We investigated six independent Vk*MYC mouse MM lines treated with an anti-BCMA TCE (Figure 6I; Methods).48–50 Two of the six Vk*MYC lines exhibited primary refractoriness to anti-BCMA TCE treatment in vivo (Supplementary Figure 7B–C). The gene discussed is MYC; the disease is Miyoshi myopathy.